Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Deborah Collyar: What's In It for Patients?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mar

Today In Oncology

Opening Session Panel Discussion

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Deborah Collyar: What's In It for Patients?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

AI As Collaborator in Cancer Research and in Clinical Care

AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?

Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma

Gedatolisib-Based Regimens in HR-Positive HER2-Negative PIK3CA Wild-Type Advanced Breast Cancer

Hyperplasia and the Link Between Obesity and Cancer